Last reviewed · How we verify
Vicks Cough Syrup for Chesty Coughs
At a glance
| Generic name | Vicks Cough Syrup for Chesty Coughs |
|---|---|
| Also known as | guaifenesin |
| Sponsor | Reckitt Benckiser Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers (PHASE1)
- Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vicks Cough Syrup for Chesty Coughs CI brief — competitive landscape report
- Vicks Cough Syrup for Chesty Coughs updates RSS · CI watch RSS
- Reckitt Benckiser Inc. portfolio CI